A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease PDF full book. Access full book title A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease by Paul J. Marangos. Download full books in PDF and EPUB format.
Author: Paul J. Marangos Publisher: Academic Press ISBN: 012812797X Category : Medical Languages : en Pages : 162
Book Description
Cancer, dementia, and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. Over the last century, we have made spectacular advances that have transformed our society – splitting the atom, space travel, telecommunications, and the Internet – but with medical research focused mostly on science for the sake of science, it has yielded precious few cures. A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease represents a "first of its kind" effort to address both the reasons for this and to posit solutions to fix our broken system, in an effort to finally end this cure crisis. Dr. Marangos draws on 45 years of experience in every aspect of the biomedical R&D field, from basic drug discovery research at the NIH to the co-founding of five drug companies. He has published 252 research papers and edited four books on drug discovery, is co-inventor on 14 patents, and founded "The Journal of Molecular Neuroscience". He argues that from a development perspective, the regulatory, patent, and legal hurdles that force industry to pursue so-called "me-too" drugs rather than cures for terminal diseases must be re-thought. Leadership accountability, strategy, focus, and urgency need to be re-evaluated, and major reforms to the NIH, FDA, and patent codes are proposed.to remedy these impediments to cures. Written for anyone frustrated with the seemingly endless threat of terminal disease, this book seeks to inform, energize, and provide the rationale for the public and industry stakeholders, as well as clinicians and researchers, to resurrect the physician-patient relationship and demand that we get serious about ridding society of this scourge on humanity. This work contains the views and opinions of the author and are in no way intended to harm the reputation of any person, agency, organization, or commercial entity discussed herein. www.cureterminaldisease.com - First comprehensive analysis of the failures in curing cancer, Alzheimer's, and cardiovascular disease with solutions proposed - Defines deficiencies in academic life science research, including conflicting incentives, QA/QC issues, and how to fix them - Provides a rationale for FDA reform especially as it relates to terminal disease drugs - Details how a reformed NIH, regulators, and industry can partner to form a NASA-type effort to speed cures of terminal diseases - Provides the first detailed roadmap for life science researchers to conquer terminal disease
Author: Paul J. Marangos Publisher: Academic Press ISBN: 012812797X Category : Medical Languages : en Pages : 162
Book Description
Cancer, dementia, and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. Over the last century, we have made spectacular advances that have transformed our society – splitting the atom, space travel, telecommunications, and the Internet – but with medical research focused mostly on science for the sake of science, it has yielded precious few cures. A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease represents a "first of its kind" effort to address both the reasons for this and to posit solutions to fix our broken system, in an effort to finally end this cure crisis. Dr. Marangos draws on 45 years of experience in every aspect of the biomedical R&D field, from basic drug discovery research at the NIH to the co-founding of five drug companies. He has published 252 research papers and edited four books on drug discovery, is co-inventor on 14 patents, and founded "The Journal of Molecular Neuroscience". He argues that from a development perspective, the regulatory, patent, and legal hurdles that force industry to pursue so-called "me-too" drugs rather than cures for terminal diseases must be re-thought. Leadership accountability, strategy, focus, and urgency need to be re-evaluated, and major reforms to the NIH, FDA, and patent codes are proposed.to remedy these impediments to cures. Written for anyone frustrated with the seemingly endless threat of terminal disease, this book seeks to inform, energize, and provide the rationale for the public and industry stakeholders, as well as clinicians and researchers, to resurrect the physician-patient relationship and demand that we get serious about ridding society of this scourge on humanity. This work contains the views and opinions of the author and are in no way intended to harm the reputation of any person, agency, organization, or commercial entity discussed herein. www.cureterminaldisease.com - First comprehensive analysis of the failures in curing cancer, Alzheimer's, and cardiovascular disease with solutions proposed - Defines deficiencies in academic life science research, including conflicting incentives, QA/QC issues, and how to fix them - Provides a rationale for FDA reform especially as it relates to terminal disease drugs - Details how a reformed NIH, regulators, and industry can partner to form a NASA-type effort to speed cures of terminal diseases - Provides the first detailed roadmap for life science researchers to conquer terminal disease
Author: Jeffrey Cummings Publisher: Cambridge University Press ISBN: 1108838669 Category : Business & Economics Languages : en Pages : 575
Book Description
Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
Author: Arnold von Eckardstein Publisher: Springer Nature ISBN: 3030860760 Category : Atherosclerosis Languages : en Pages : 537
Book Description
This open access book is supported by the European Atherosclerosis Society Association (EAS). This follow-up edition of the well-received Handbook volume 'Atherosclerosis: Diet and Drugs' reflects the state-of-the-art and most recent developments in atherosclerosis research. Outstanding international experts give a comprehensive overview of the field covering topics, such as improving the treatment focusing on established targets, novel drug developments addressing pre-defined targets, hypothesis-based and hypothesis-free approaches to unravel novel targets.
Author: Leonard F. M. Scinto Publisher: Springer Science & Business Media ISBN: Category : Medical Languages : en Pages : 384
Book Description
The three major approaches to diagnosis of AD -- radiological, biological, and neurophysiological -- are discussed in detail with chapters highlighting the most promising technologies within these approaches. The leading authors, all of whom are intimately involved with these emerging technologies, have developed this as an essential reference for neuropathologists, clinicians and researchers of Alzheimer's disease.
Author: National Academies of Sciences Engineering and Medicine Publisher: ISBN: 9780309495035 Category : Languages : en Pages :
Book Description
As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.
Author: Publisher: Academic Press ISBN: 012823122X Category : Medical Languages : en Pages : 322
Book Description
Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer's and Parkinson's, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases; Harnessing Neurogenesis in the Adult Brain – A Role in Type 2 Diabetes Mellitus and Alzheimer's disease; and much more. - Summarizes the impact of the metabolic hypothesis on underlying mechanisms of neurodegenerative diseases - Presents novel, potential treatment strategies based on the metabolic hypothesis for neurodegenerative diseases
Author: Dean Sherzai Publisher: HarperCollins ISBN: 0062666495 Category : Health & Fitness Languages : en Pages : 218
Book Description
A revolutionary, proven program for reversing the symptoms of Alzheimer's disease and cognitive decline from award winning neurologists and codirectors of the Brain Health and Alzheimer's Prevention Program at Loma Linda University Medical Center Over 47 million people are currently living with Alzheimer’s disease worldwide. While all other major diseases are in decline, deaths from Alzheimer’s have increased radically. What you or your loved ones don’t yet know is that 90 percent of Alzheimer’s cases can be prevented. Based on the largest clinical and observational study to date, neurologists and codirectors of the Brain Health and Alzheimer’s Prevention Program at Loma Linda University Medical Center, Drs. Dean and Ayesha Sherzai, offer in The Alzheimer’s Solution the first comprehensive program for preventing Alzheimer’s disease and improving cognitive function. Alzheimer’s disease isn’t a genetic inevitability, and a diagnosis does not need to come with a death sentence. Ninety percent of grandparents, parents, husbands, and wives can be spared. Ninety percent of us can avoid ever getting Alzheimer’s, and for the 10 percent with strong genetic risk for cognitive decline, the disease can be delayed by ten to fifteen years. This isn’t an estimate or wishful thinking; it’s a percentage based on rigorous science and the remarkable results the Sherzais have seen firsthand in their clinic. This much-needed revolutionary book reveals how the brain is a living universe, directly influenced by nutrition, exercise, stress, sleep, and engagement. In other words: what you feed it, how you treat it, when you challenge it, and the ways in which you allow it to rest. These factors are the pillars of the groundbreaking program you’ll find in these pages, which features a personalized assessment for evaluating risk, a five-part program for prevention and symptom-reversal, and day-by-day guides for optimizing cognitive function. You can prevent Alzheimer’s disease from affecting you, your family, friends, and loved ones. Even with a diagnosis, you can reverse cognitive decline and add vibrant years to your life. The future of your brain is finally within your control.
Author: World Health Organization Publisher: ISBN: 9789241564854 Category : Medical Languages : en Pages : 0
Book Description
This global status report on prevention and control of NCDs (2014), is framed around the nine voluntary global targets. The report provides data on the current situation, identifying bottlenecks as well as opportunities and priority actions for attaining the targets. The 2010 baseline estimates on NCD mortality and risk factors are provided so that countries can report on progress, starting in 2015. In addition, the report also provides the latest available estimates on NCD mortality (2012) and risk factors, 2010-2012. All ministries of health need to set national NCD targets and lead the development and implementation of policies and interventions to attain them. There is no single pathway to attain NCD targets that fits all countries, as they are at different points in their progress in the prevention and control of NCDs and at different levels of socioeconomic development. However all countries can benefit from the comprehensive response to attaining the voluntary global targets presented in this report.--Publisher description.
Author: Great Britain: Department of Health Publisher: The Stationery Office ISBN: 9780101798525 Category : Medical Languages : en Pages : 104
Book Description
The Government recognises that many lifestyle-driven health problems are at alarming levels: obesity; high rates of sexually transmitted infections; a relatively large population of drug users; rising levels of harm from alcohol; 80,000 deaths a year from smoking; poor mental health; health inequalities between rich and poor. This white paper outlines the Government's proposals to protect the population from serious health threats; help people live longer, healthier and more fulfilling lives; and improve the health of the poorest. It aims to empower individuals to make healthy choices and give communities and local government the freedom, responsibility and funding to innovate and develop ways of improving public health in their area. The paper responds to Sir Michael Marmot's strategic review of health inequalities in England post 2010 - "Fair society, healthy lives" (available at http://www.marmotreview.org/AssetLibrary/pdfs/Reports/FairSocietyHealthyLives.pdf) and adopts its life course framework for tackling the wider social determinants of health. A new dedicated public health service - Public Health England - will be created to ensure excellence, expertise and responsiveness, particularly on health protection where a national response is vital. The paper gives a timetable showing how the proposals will be implemented and an annex sets out a vision of the role of the Director of Public Health. The Department is also publishing a fuller story on the health of England in "Our health and wellbeing today" (http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_122238.pdf), detailing the challenges and opportunities, and in 2011 will issue documents on major public health issues.
Author: Paul J. Marangos
Author: Paul J. Marangos
Author: Jeffrey Cummings
Author: Arnold von Eckardstein
Author: Leonard F. M. Scinto
Author: National Academies of Sciences Engineering and Medicine
Author: 
Author: Dean Sherzai
Author: World Health Organization
Author: Great Britain: Department of Health
Author: Krupakar Parthasarathy